Stefan Schillberg

Dr. Stefan Schillberg

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 December 2003 in Trends in Biotechnology
Verified
Journal Article
Closed access
RTRichard Twyman
Richard Twyman
ESEva Stoger
Eva Stoger
SSStefan Schillberg
Stefan Schillberg
PCPaul Christou
Paul Christou
RFRainer Fischer
Rainer Fischer

1 April 2004 in Current Opinion in Plant Biology
Verified
Journal Article
Closed access
RFRainer Fischer
Rainer Fischer
ESEva Stoger
Eva Stoger
SSStefan Schillberg
Stefan Schillberg
PCPaul Christou
Paul Christou
RTRichard Twyman
Richard Twyman

1 July 2005 in EMBO Reports
Verified
Journal Article
Closed access
JMJulian K ‐C. Ma
Julian K ‐C. Ma
EBEugenia Barros
Eugenia Barros
RBRalph Bock
Ralph Bock
PCPaul Christou
Paul Christou
PDPhilip J. Dale
Philip J. Dale
RTRichard Twyman
Richard Twyman

11 June 2019 in Frontiers in Plant Science
Verified
Journal Article
Open access
PDF file
SSStefan Schillberg
Stefan Schillberg
NRNicole Raven
Nicole Raven
HSHolger Spiegel
Holger Spiegel
SRStefan Rasche
Stefan Rasche
MBMatthias Buntru
Matthias Buntru
Over the last three decades, the expression of recombinant proteins in plants and plant cells has been promoted as an alternative cost-effective production platform. However, the market is still dominated by prokaryotic and mammalian expression systems, the former offering high production capacity at a low cost, and the latter favored for the production of complex biopharmaceutical products. Although plant systems are now gaining widespread acceptance as a platform for the larger-scale production of recombinant proteins, there is still resistance to commercial uptake. This partly reflects the relatively low yields achieved in plants, as well as inconsistent product quality and difficulties with larger-scale downstream processing. Furthermore, there are only a few cases in which plants have demonstrated economic advantages compared to established and approved commercial processes, so industry is reluctant to switch to plant-based production. Nevertheless, some plant-derived proteins for research or cosmetic/pharmaceutical applications have reached the market, showing that plants can excel as a competitive production platform in some niche areas. Here, we discuss the strengths of plant expression systems for specific applications, but mainly address the bottlenecks that must be overcome before plants can compete with conventional systems, enabling the future commercial utilization of plants for the production of valuable proteins.

28 September 1999 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
CVCarmen Vaquero
Carmen Vaquero
MSMarkus Sack
Markus Sack
JCJohn Chandler
John Chandler
JDJürgen Drossard
Jürgen Drossard
FSFlora Schuster
Flora Schuster
RFRainer Fischer
Rainer Fischer
To evaluate the expression of different forms of a tumor-specific antibody in plants, we adapted a recently described Agrobacterium - mediated transient expression system. A recombinant single-chain Fv antibody (scFvT84.66) and a full-size mouse/human chimeric antibody (cT84.66) derived from the parental murine mAb T84.66 specific for the human carcinoembryonic antigen were engineered into a plant expression vector. Chimeric T84.66 heavy and light chain genes were constructed by exchanging the mouse light and heavy chain constant domain sequences with their human counterparts and cloned into two independent plant expression vectors. In vivo assembly of full-size cT84.66 was achieved by simultaneous expression of the light and heavy chains after vacuum infiltration of tobacco leaves with two populations of recombinant Agrobacterium . Upscaling the transient system permitted purification of functional recombinant antibodies from tobacco leaf extracts within a week. His6-tagged scFvT84.66 was purified by immobilized metal affinity chromatography and cT84.66 by protein A affinity chromatography. Sufficient amounts of recombinant antibodies were recovered for detailed characterization by SDS/PAGE, Western blotting, and ELISA.

1 March 2012 in Biotechnology Advances
Verified
Journal Article
Closed access
RFRainer Fischer
Rainer Fischer
SSStefan Schillberg
Stefan Schillberg
SHStephan Hellwig
Stephan Hellwig
RTRichard Twyman
Richard Twyman
JDJuergen Drossard
Juergen Drossard